161,876 Shares in Biohaven Ltd. $BHVN Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in shares of Biohaven Ltd. (NYSE:BHVN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 161,876 shares of the company’s stock, valued at approximately $1,369,000.

Other hedge funds have also modified their holdings of the company. PNC Financial Services Group Inc. raised its stake in shares of Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after purchasing an additional 1,268 shares during the last quarter. IFP Advisors Inc boosted its position in Biohaven by 55.4% in the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after buying an additional 1,450 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Biohaven by 178.4% in the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after buying an additional 2,583 shares during the period. Arax Advisory Partners increased its holdings in Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock worth $55,000 after buying an additional 4,443 shares during the period. Finally, Leonteq Securities AG purchased a new position in Biohaven during the 4th quarter worth approximately $78,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Canaccord Genuity Group initiated coverage on shares of Biohaven in a research report on Monday, April 13th. They set a “buy” rating and a $21.00 target price for the company. Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. HC Wainwright reaffirmed a “neutral” rating and set a $10.00 price target on shares of Biohaven in a research report on Tuesday, May 26th. Finally, Bank of America reiterated an “underperform” rating and set a $11.00 price objective (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.62.

Biohaven Stock Performance

NYSE BHVN traded down $1.19 during mid-day trading on Friday, reaching $15.60. 2,128,443 shares of the stock were exchanged, compared to its average volume of 3,724,918. The business’s 50 day moving average is $12.02 and its 200-day moving average is $11.17. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The company has a market capitalization of $2.35 billion, a P/E ratio of -2.75 and a beta of 1.28. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, equities research analysts forecast that Biohaven Ltd. will post -3.1 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.